Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.45

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.04

EPS Last/This Y

0.28

EPS This/Next Y

0.52

Price

0.77

Target Price

3.5

Analyst Recom

1

Performance Q

-46.33

Relative Volume

0.24

Beta

0.66

Ticker: NXTC




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19NXTC0.9250.000.0049
2024-12-20NXTC0.970.000.0049
2024-12-23NXTC0.943N/AN/A0
2024-12-24NXTC0.868N/AN/A0
2024-12-26NXTC0.8629N/AN/A0
2024-12-27NXTC0.82310.000.0021
2024-12-30NXTC0.8030.000.0021
2024-12-31NXTC0.770.000.0021
2025-01-02NXTC0.79360.000.0021
2025-01-03NXTC0.84090.000.0026
2025-01-06NXTC0.91760.000.0029
2025-01-07NXTC0.90.000.0029
2025-01-08NXTC0.8350.000.0029
2025-01-09NXTC0.8510.000.0029
2025-01-10NXTC0.79620.000.0029
2025-01-13NXTC0.77010.000.0029
2025-01-14NXTC0.790.000.0047
2025-01-15NXTC0.76810.000.0047
2025-01-16NXTC0.770.000.0047
2025-01-17NXTC0.78450.000.0047
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19NXTC0.9527.9- -1.97
2024-12-20NXTC0.9727.9- -1.97
2024-12-23NXTC0.9427.9- -1.97
2024-12-24NXTC0.8727.9- -1.97
2024-12-26NXTC0.8327.9- -1.97
2024-12-27NXTC0.8227.9- -1.97
2024-12-30NXTC0.8027.9- -1.97
2024-12-31NXTC0.7927.9- -1.97
2025-01-02NXTC0.8227.9- -1.97
2025-01-03NXTC0.8227.9- -1.97
2025-01-06NXTC0.9227.9- -1.97
2025-01-07NXTC0.8927.9- -1.97
2025-01-08NXTC0.8527.9- -1.97
2025-01-09NXTC0.8527.9- -1.97
2025-01-10NXTC0.8027.9- -1.97
2025-01-13NXTC0.7827.9- -1.97
2025-01-14NXTC0.7827.9- -1.97
2025-01-15NXTC0.7927.9- -1.97
2025-01-16NXTC0.7727.9- -1.97
2025-01-17NXTC0.7727.9- -1.97
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19NXTC0.00-1.890.24
2024-12-20NXTC0.00-1.890.24
2024-12-23NXTC0.00-1.890.24
2024-12-24NXTC0.00-1.890.24
2024-12-26NXTC0.00-1.890.24
2024-12-27NXTC0.00-1.890.24
2024-12-30NXTC0.00-1.870.24
2024-12-31NXTC0.00-1.870.24
2025-01-02NXTC0.00-1.870.24
2025-01-03NXTC0.00-1.870.24
2025-01-06NXTC0.00-1.890.24
2025-01-07NXTC0.00-1.890.24
2025-01-08NXTC0.00-1.890.24
2025-01-09NXTC0.00-1.890.24
2025-01-10NXTC0.00-1.890.24
2025-01-13NXTC0.00-1.890.45
2025-01-14NXTC0.00-1.890.45
2025-01-15NXTC0.00-1.890.45
2025-01-16NXTC0.00-1.890.45
2025-01-17NXTC0.00-1.890.45
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.41

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.37

Insider Transactions

Institutional Transactions

-1.89

Beta

0.66

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

21

Sentiment Score

29

Actual DrawDown %

98.6

Max Drawdown 5-Year %

-98.6

Target Price

3.5

P/E

Forward P/E

PEG

P/S

P/B

0.29

P/Free Cash Flow

EPS

-2.09

Average EPS Est. Cur. Y​

-1.97

EPS Next Y. (Est.)

-1.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.24

Return on Equity vs Sector %

-96.5

Return on Equity vs Industry %

-83.9

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.39

EBIT Estimation

NextCure, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 82
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading